{"nct_id":"NCT03011034","title":"Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment","status":"COMPLETED","status_verified_date":"2025-03","start_date":"2017-02-14","start_date_type":"ACTUAL","primary_completion_date":"2019-01-23","primary_completion_date_type":"ACTUAL","completion_date":"2021-10-05","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["JNJ"]}